# EDGAR Filing Document

**Accession Number:** 0001809122
**File Stem:** 0001104659-23-040167
**Filing Date:** 2023-3
**Character Count:** 4514
**Document Hash:** bb78c581ecc8df7954697500dbb7eeca
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-040167.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0001104659-23-040167

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230331

**FILED AS OF DATE**: 20230331

**DATE AS OF CHANGE**: 20230331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CureVac N.V.
- **CENTRAL INDEX KEY:** 0001809122
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39446
- **FILM NUMBER:** 23787661

**BUSINESS ADDRESS:**
- **STREET 1:** PAUL-EHRLICH-STRABE 15 TUBINGEN
- **CITY:** BADEN-WURTTEMBERG
- **STATE:** 2M
- **ZIP:** 72076
- **BUSINESS PHONE:** 49 7071 9883 0

**MAIL ADDRESS:**
- **STREET 1:** PAUL-EHRLICH-STRABE 15 TUBINGEN
- **CITY:** BADEN-WURTTEMBERG
- **STATE:** 2M
- **ZIP:** 72076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CureVac B.V.
- **DATE OF NAME CHANGE:** 20200410

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE** 

**SECURITIES EXCHANGE ACT OF 1934**

For the month of March, 2023

**Commission File Number: 001-39446**

**CureVac N.V.**

(*Exact Name of Registrant as Specified in Its Charter*)

**Friedrich-Miescher-Strasse 15, 72076**

**Tübingen, Germany**

**+49 7071 9883 0**

*(Address of principal executive office)*

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ⌧ Form 40-F ◻

On March 31, 2023, CureVac N.V. (the "Company") issued a table containing tabulations of the votes cast at the Company's extraordinary general meeting of shareholders.

The information in this Form 6-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| CUREVAC N.V. | CUREVAC N.V. |
| By: | /s/ Franz-Werner Haas, LLD, LLM |
|  | *Chief Executive Officer* |

---

Date: March 31, 2023

EXHIBIT INDEX

---

| | |
|:---|:---|
| EXHIBIT NO. | DESCRIPTION |
| [99.1](tm2311188d1_ex99-1.htm) | [Final Tabulation Table of Votes Cast on the Company's Extraordinary General Meeting of Shareholders.](tm2311188d1_ex99-1.htm) |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| CureVac N.V., Tübingen, Germany | ![](tm2311188d1_ex99-1img01.jpg) |
| Extraordinary General Meeting of Shareholders, March 28, 2023 | ![](tm2311188d1_ex99-1img01.jpg) |

---

**Voting results – Overview**

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Agenda Item 2 | &nbsp;&nbsp;Appointment of Dr. Alexander Zehnder as managing director of the Company - accepted | &nbsp;&nbsp;Appointment of Dr. Alexander Zehnder as managing director of the Company - accepted |
| &nbsp;&nbsp;159.164.046 | &nbsp;&nbsp;Number of shares for which valid votes were cast (= 71.10 % of the registered share capital) | &nbsp;&nbsp;Number of shares for which valid votes were cast (= 71.10 % of the registered share capital) |
| &nbsp;&nbsp;159.060.946 | &nbsp;&nbsp;Yes votes | &nbsp;&nbsp;99.94 % of the valid votes cast |
| &nbsp;&nbsp;89.959 | &nbsp;&nbsp;No votes | &nbsp;&nbsp;0.05 % of the valid votes cast |
| &nbsp;&nbsp;Agenda Item 3 | &nbsp;&nbsp;Appointment of Myriam Mendila, MD as managing director of the Company - accepted | &nbsp;&nbsp;Appointment of Myriam Mendila, MD as managing director of the Company - accepted |
| &nbsp;&nbsp;159.164.046 | &nbsp;&nbsp;Number of shares for which valid votes were cast (= 71.10 % of the registered share capital) | &nbsp;&nbsp;Number of shares for which valid votes were cast (= 71.10 % of the registered share capital) |
| &nbsp;&nbsp;159.065.670 | &nbsp;&nbsp;Yes votes | &nbsp;&nbsp;99.94 % of the valid votes cast |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;89.868 | &nbsp;&nbsp;No votes | &nbsp;&nbsp;0.05 % of the valid votes cast |

---